EVG Evgen Pharma Plc

TIDMEVG

RNS Number : 3689T

Evgen Pharma PLC

22 July 2022

Evgen Pharma plc

("Evgen" or the "Company")

Result of AGM and Investor Presentation

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, held its AGM yesterday, on 21 July 2022, where all resolutions were passed. The AGM voting results are available on the Company's website HERE .

Following the completion of the AGM, Dr Huw Jones, the CEO and Richard Moulson, CFO held a virtual presentation for investors via the Investor Meet platform. The presentation was recorded and can be viewed HERE .

-Ends-

Enquiries:

 
 Evgen Pharma plc 
  Dr Huw Jones, CEO 
  Richard Moulson, CFO                                   +44 1625 466591 
 FinnCap (Nominated Advisor and Broker) 
  Geoff Nash / Teddy Whiley (Corporate Finance) 
  Alice Lane/Nigel Birks (ECM)                          +44 20 7220 0500 
 Instinctif Partners                                    +44 207 457 2020 
  Melanie Toyne-Sewell / Rozi Morris / Agnes        Evgen@Instinctif.com 
  Stephens / Adam Loudon 
 

Notes to Editors

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. It will be entering the clinic in glioma/glioblastoma later in 2022. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex(R) technology.

The Company commenced operations in January 2008 and has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEAXXFALAAEFA

(END) Dow Jones Newswires

July 22, 2022 02:00 ET (06:00 GMT)

Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024